TAK-853 在叶酸受体 Alpha 阳性晚期卵巢癌和其他实体瘤成人参与者中的研究
一项 1/2 期开放标签研究,旨在评估 Mirvetuximab Soravtansine (TAK-853) 在日本叶酸受体 Alpha 阳性晚期卵巢癌和其他实体瘤患者中的安全性、耐受性、有效性和药代动力学
这项研究的主要目的是检查 TAK-853 的副作用,检查参与者可以接受多少 TAK-853 而不会产生副作用,检查 TAK-853 控制症状的效果,并检查 TAK-853 的用量随着时间的推移留在他们的血液中。
该研究将分两个阶段进行,包括第一阶段和第二阶段。 在第一阶段,参与者在第一次注射后将在医院至少呆 3 天,进行一些测试并检查治疗是否有任何副作用。 在第二阶段,参与者将多次访问他们的研究医院。 在这两个阶段中,参与者将在每个 3 周周期的第一天收到 TAK-853。
参与者将在第 1 阶段部分参与研究约 9 个月,在第 2 阶段部分参与研究约 24 个月。 研究医生将检查研究治疗的副作用。
研究概览
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
-
Chiba、日本
- Chiba University Hospital
-
Kyoto、日本
- Kyoto University Hospital
-
Okayama、日本
- Okayama University Hospital
-
Osaka、日本
- Osaka International Cancer Institute
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本
- Aichi Cancer Center
-
-
Chiba
-
Kashiwa、Chiba、日本
- National Cancer Center Hospital East
-
Kashiwa、Chiba、日本
- Jikei University Kashiwa Hospital
-
-
Ehime
-
Matsuyama、Ehime、日本
- Shikoku Cancer Center
-
-
Fukuoka
-
Kurume、Fukuoka、日本
- Kurume University Hospital
-
-
Hokkaido
-
Sapporo、Hokkaido、日本
- Hokkaido University Hospital
-
Sapporo、Hokkaido、日本
- Sapporo Medical University Hospital
-
-
Hyōgo
-
Akashi、Hyōgo、日本
- Hyogo Cancer Center
-
-
Iwate
-
Shiwa-gun、Iwate、日本
- Iwate Medical University Hospital
-
-
Miyagi
-
Sendai、Miyagi、日本
- Tohoku University Hospital
-
-
Saitama
-
Hidaka、Saitama、日本
- Saitama Medical University International Medical Center
-
-
Shizuoka
-
Nakatogari、Shizuoka、日本
- Shizuoka Cancer Center
-
-
Tokyo
-
Chuo-ku、Tokyo、日本
- National Cancer Center Hospital
-
Koto-ku、Tokyo、日本
- Cancer Institute Hospital of JFCR
-
Minato-ku、Tokyo、日本
- The Jikei University Hospital
-
Shinjuku-ku、Tokyo、日本
- Keio University Hospital
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:
第一阶段部分:
诊断、允许的既往治疗和疾病可测量性要求:
所有参与者必须有病理记录,已知表达叶酸受体α(FRα)的晚期实体瘤,对标准治疗有抵抗力或难治性,没有可用的标准治疗,或者参与者拒绝标准治疗。
- 卵巢癌
- 子宫内膜癌
- 非小细胞肺癌(NSCLC)
- 三阴性乳腺癌(TNBC)
- 胆管癌
- 结直肠癌 (CRC)
- 胃食管腺癌 注意:只要事先有肿瘤 FR α 表达的记录,患有上述以外实体瘤类型的参与者就有资格。
- 所有事先未通过免疫组织化学 (IHC) 记录肿瘤 FR α 表达的参与者必须愿意提供存档肿瘤组织块或切片,或接受使用低风险、医学常规程序获取新活检的程序,以进行 FR α 的 IHC 确认>=1% 的活肿瘤细胞的膜染色强度 >=1+ 呈阳性,进入第 1 阶段部分
- 参与者之前可能接受的细胞毒性或靶向治疗的数量没有上限。 参与者可能之前接受过针对叶酸受体的研究化合物的治疗。
- 根据实体瘤反应评估标准 (RECIST) 1.1,参与者必须患有可测量或不可测量的疾病(例如无法准确测量的大腹部肿块)。
- 参与者的东部肿瘤合作组表现状态 (ECOG PS) 必须为 0 或 1
距先前治疗的时间:
- 全身抗肿瘤治疗:五个半衰期或 4 周,以较短者为准(先前使用亚硝基脲或丝裂霉素 C 为 6 周)
- FR α靶向治疗:五个半衰期或四周,以较长者为准
- 放射治疗:广视野放射治疗(例如 影响至少 30% 的骨髓)在开始研究药物之前完成至少四个星期,或局灶性放射至少完成两周
- 参与者必须已从所有先前治疗相关的毒性中稳定或恢复(1 级或基线)
- 大手术必须在首次注射 TAK-853 之前四个星期完成。 在研究治疗之前,参与者必须已从副作用中恢复或稳定下来。
参与者必须具有足够的血液学、肝脏和肾脏功能,如以下参数所定义:
- 中性粒细胞绝对计数 (ANC) >= 1.5*10^9/L (1,500/微升) 前 10 天无粒细胞集落刺激因子 (G-CSF) 或前 10 天内无长效白细胞 (WBC) 生长因子20天
- 血小板计数>=100.0*10^9/L(100,000/微升;前10天内未输注血小板)
- 前 21 天内未输注浓缩红细胞 (PRBC) 血红蛋白 >= 9.0 g/dL
- 血清肌酐 =< 1.5* 正常上限 (ULN) 或估计肌酐清除率 >= 30 mL/分钟(使用 Cockcroft Gault 方程计算),
- 天冬氨酸转氨酶 (AST) =< 2.5* ULN;丙氨酸转氨酶 (ALT) =< 2.5* ULN(AST、ALT < 5* ULN,如果有肝转移),并且
- 总胆红素 =< 1.5* ULN(如果总胆红素 < 3.0* ULN,则有吉尔伯特综合征诊断记录的参与者符合资格)
- 患有中枢神经系统 (CNS) 疾病的参与者如果在研究第 1 天之前至少 4 周已切除脑转移瘤或接受过放射治疗,并且满足以下所有标准,则符合资格:
- 残余神经系统症状 =< 1 级
- 不需要地塞米松,并且
- 后续 MRI 显示治疗的病变没有进展,也没有出现新的病变。
第二阶段部分:
- 参与者必须确诊为高级别浆液性上皮性卵巢癌、原发性腹膜癌或输卵管癌
参与者必须患有铂类耐药疾病:
- 仅接受过 1 线铂类治疗的参与者必须接受至少 4 个周期的铂类治疗,必须有缓解(完全缓解 [CR] 或部分缓解 [PR]),然后在 > 3 个月和 =< 之间取得进展最后一次铂类给药日期后 6 个月
- 已接受 2 或 3 线铂类治疗的参与者必须在最后一次铂类治疗日期或之后 6 个月内出现进展 注意:进展应从最后一次给予铂类治疗剂量的日期到开始治疗的日期计算。放射影像显示进展 注意:一线治疗期间原发性铂类难治性的参与者被排除在外(参见排除标准)
- 参与者必须在最近一次治疗期间或之后在放射学上取得进展
- 参与者必须愿意提供存档的肿瘤组织块或切片,或接受使用低风险、医学常规程序获得新活检的程序,以根据 Ventana FOLR1 的定义进行 IHC 确认 FR α 表达(报告为“阳性”)化验。 肿瘤必须被确认为 FR α 高,定义为≥75% 的活肿瘤细胞的 FR α 阳性,膜染色强度≥2+,才能进入第 2 阶段。
- 参与者必须至少有一个符合 RECIST v1.1 标准可测量疾病定义的病变(由研究者进行放射学测量)。
参与者之前必须接受过至少 1 种但不超过 3 种全身性抗癌治疗,并且单药治疗适合作为下一种治疗:
A。新辅助 +- 辅助被视为一种治疗方案 b. 维持治疗(例如贝伐珠单抗、聚 ADP 核糖聚合酶 [PARP] 抑制剂)将被视为先前治疗方案的一部分(即不独立计算) c. 在没有进展的情况下因毒性而改变的治疗将被视为同一系列的一部分(即不独立计算) d. 激素治疗将被视为单独的治疗方案,除非作为维持治疗进行
- 参与者的 ECOG PS 必须为 0 或 1
距上次治疗的时间:
- 全身抗肿瘤治疗(5个半衰期或4周,以较短者为准)
- 首次给药研究药物前至少 2 周完成局部放疗
- 参与者必须已从所有先前治疗相关的毒性中稳定或恢复(1 级或基线)
- 大手术必须在第一次给药前至少 4 周完成,并且参与者必须已从先前手术的副作用中恢复或稳定下来
参与者必须具有足够的血液学、肝脏和肾脏功能,定义为:
- ANC >= 1.5* 10^9/L (1,500/微升) 前 10 天内无 G-CSF 或前 20 天内无长效 WBC 生长因子
- 前 10 天内未输注血小板,血小板计数 >= 100* 10^9/L(100,000/微升)
- 前 21 天内未输注 PRBC 血红蛋白 >= 9.0 g/dL
- 血清肌酐 =< 1.5* ULN 或估计肌酐清除率 >= 30 mL/分钟(使用 Cockcroft Gault 方程计算)。
- AST 和 ALT =< 3.0* ULN
- 总胆红素 =< 1.5* ULN(如果总胆红素 < 3.0* ULN,则有吉尔伯特综合征诊断记录的参与者符合资格)
- 血清白蛋白 >= 2 g/dL
排除标准:
第一阶段部分:
- 根据美国国家癌症研究所不良事件通用术语标准 (NCI CTCAE) v5.0,患有 > 1 级周围神经病变的参与者
- 患有活动性或慢性角膜疾病、角膜移植史或需要持续治疗/监测的活动性眼部疾病的参与者,例如不受控制的青光眼、需要玻璃体内注射的湿性年龄相关性黄斑变性、伴有黄斑水肿的活动性糖尿病视网膜病变、黄斑变性、存在视乳头水肿和/或单眼视觉。
严重并发疾病,包括但不限于以下情况:
临床相关的活动性感染,包括 - 活动性乙型或丙型肝炎感染(无论是否接受积极的抗病毒治疗)
- 人类免疫缺陷病毒(HIV)感染
- 活动性巨细胞病毒感染
- 活跃的 COVID-19/SARS-CoV-2 感染。 尽管 SARS-CoV-2 检测不是研究进入的强制性要求,但检测应遵循当地的临床实践指南和标准
- 开始研究药物前 2 周内需要静脉注射抗生素的任何其他已知并发传染病 注意:需要在筛查肝炎时进行测试,而除非有临床指征,否则上述其余感染不需要进行测试。 已知乙型肝炎表面抗原血清阳性和/或可检测到丙型肝炎病毒 RNA 的参与者将被排除。 乙型肝炎核心抗体和/或乙型肝炎表面抗体呈阳性的参与者可以入组,但血清乙型肝炎病毒 DNA 必须检测不到。 丙型肝炎病毒抗体呈阳性的参与者的丙型肝炎病毒 RNA 血清水平必须达到不可检测的水平。 将根据《预防免疫抑制治疗或化疗引起的乙型肝炎病毒感染再激活指南》(日本肝病学会 2022 年)对参与者进行监测和管理。
患有临床显着心脏病的参与者,包括但不限于以下任何一种:
- 首次服用研究药物前 6 个月内发生心肌梗塞
- 不稳定型心绞痛
- 不受控制的充血性心力衰竭(纽约心脏协会 > II 级)
- 不受控制 >= 3 级高血压(根据 NCI CTCAE v5.0)
- 不受控制的心律失常
- 严重主动脉瓣狭窄
- >= 既往化疗后出现 3 级心脏毒性
- 多发性硬化症或其他脱髓鞘疾病、Lambert-Eaton 综合征(副肿瘤综合征)病史、过去六个月内出血性或缺血性中风病史或酒精性肝病病史。
- 既往临床诊断为间质性肺疾病 (ILD),包括肺炎。
- 任何其他伴随的抗癌治疗,例如免疫疗法、生物疗法、放疗、化疗、研究性疗法或高剂量类固醇;然而,对于患有前列腺癌的参与者,允许使用稳定>= 14天的低剂量类固醇和黄体生成素释放激素(LHRH)
- 已知对先前的单克隆抗体疗法或美登木素生物碱或研究药物和/或其任何赋形剂过敏
- 过去 3 年内有实体瘤恶性肿瘤病史,经过充分治疗的基底细胞或鳞状细胞皮肤癌、原位宫颈癌、原位乳腺癌、原位前列腺癌(参与者必须在 2 年内没有表现出活动性疾病的证据)入学前)
- 需要使用含叶酸补充剂的参与者(例如叶酸缺乏)
- 先前接受过同种异体或自体骨髓移植的参与者
第二阶段部分:
- 具有子宫内膜样、透明细胞、粘液性或肉瘤组织学、含有任何上述组织学的混合肿瘤或低度或交界性卵巢肿瘤的参与者
- 患有原发性铂难治性疾病的参与者,定义为对一线含铂化疗最后一剂后 3 个月内无反应(CR 或 PR)或病情进展的疾病
- 先前接受过影响至少 20% 骨髓的宽视野放疗的参与者
- 根据 NCI CTCAE v5.0 患有 > 1 级周围神经病变的参与者
- 患有活动性或慢性角膜疾病、角膜移植史或需要持续治疗/监测的活动性眼部疾病的参与者,例如不受控制的青光眼、需要玻璃体内注射的湿性年龄相关性黄斑变性、伴有黄斑水肿的活动性糖尿病视网膜病变、黄斑变性、存在视乳头水肿和/或单眼视觉
患有严重并发疾病或临床相关活动性感染的参与者,包括但不限于以下情况:
- 活动性乙型或丙型肝炎感染(无论是否接受积极的抗病毒治疗)
- 艾滋病毒感染
- 活动性巨细胞病毒感染
- 活跃的 COVID-19/SARS-CoV-2 感染。 尽管 SARS-CoV-2 检测对于进入研究并不是强制性的,但检测应遵循当地的临床实践指南和标准。
- 开始研究药物前 2 周内需要静脉注射抗生素的任何其他并发传染病 注意:在筛查肝炎 (a) 时需要进行测试,而对于上述 (b-e) 的其余感染则不需要进行测试,除非有临床指征。
已知乙型肝炎表面抗原血清阳性和/或可检测到丙型肝炎病毒 RNA 的参与者将被排除。 乙型肝炎核心抗体和/或乙型肝炎表面抗体呈阳性的参与者可以入组,但血清乙型肝炎病毒 DNA 必须检测不到。
丙型肝炎病毒抗体呈阳性的参与者的丙型肝炎病毒 RNA 血清水平必须达到不可检测的水平。 将根据《预防免疫抑制治疗或化疗引起的乙型肝炎病毒感染再激活指南》(日本肝病学会 2022 年)对参与者进行监测和管理。
7. 患有多发性硬化症或其他脱髓鞘疾病和/或 Lambert-Eaton 综合征(副肿瘤综合征)病史的参与者 8. 患有临床显着心脏病的参与者,包括但不限于以下任何一种:
- 首次服用研究药物前 6 个月内发生心肌梗塞
- 不稳定型心绞痛
- 不受控制的充血性心力衰竭(纽约心脏协会 > II 级)
- 不受控制 >= 3 级高血压(根据 NCI CTCAE v5.0)
- 不受控制的心律失常 9. 首次服用 TAK-853 之前六个月内有出血性或缺血性中风病史的参与者 10. 有肝硬化肝病史的参与者(Child-Pugh B 级或 C 级) 11. 既往临床诊断为 ILD(包括肺炎)的参与者 12. 需要使用含叶酸补充剂的参与者(例如叶酸缺乏) 13. 既往对单克隆抗体或美登木素生物碱过敏的参与者 14。 先前接受过 TAK-853 或其他 FR α 靶向药物治疗的参与者 15. 患有未经治疗或有症状的中枢神经系统转移的参与者 16. 首次服用 TAK-853 前 3 年内有其他恶性肿瘤病史的参与者 注:不包括转移或死亡风险可忽略不计的肿瘤(例如,充分控制的基底细胞癌或皮肤鳞状细胞癌、或子宫颈或乳腺原位癌) 17. 先前已知对研究药物和/或其任何赋形剂的过敏反应
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:第一阶段部分和第二阶段部分:TAK-853
TAK-853,6.0 mg/kg,注射,静脉内 (IV),每 3 周一次。
患者将继续接受研究药物,直到疾病进展、不可接受的毒性、撤回同意、死亡,或直到申办者终止研究(以先发生者为准)。
|
TAK-853静脉注射液
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1
大体时间:Up to Cycle 1 (up to 21 days)
|
DLT was evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) V5.0 and defined as any of following events: 1.
If re-treatment was not initiated within 14 days due to adverse event (AE) related to protocol treatment; 2. Grade 4 neutropenia for more than 7 days; 3. Grade 3 or 4 neutropenia with single temperature reading >= 38.3-degree Celsius (°C) or sustained temperature reading of greater than (>) 38°C for >1 hour; 4. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except following cases, AEs related to underlying disease, Alopecia, Grade 3 fatigue, Lymphopenia unless accompanied by clinically significant infection, isolated and asymptomatic Grade 3 abnormalities in biochemistry laboratory values that last for less than and equal to (<=) 7 days including electrolyte abnormalities.
|
Up to Cycle 1 (up to 21 days)
|
|
Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
An AE means any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product whether or not it is related to the medicinal product.
This includes any newly occurring event, or a previous condition that has increased in severity or frequency since the administration of study drug.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With Grade 3 or Higher TEAEs by Severity
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
The severity grade was evaluated as per the NCI CTCAE Version 5.0, where Grade 1 scales as Mild (asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated); Grade 2 scales as Moderate (minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living [ADL]); Grade 3 was severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL), Grade 4 was life-threatening consequences; urgent intervention indicated, and Grade 5 was death related to AE. TEAEs were AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurs first.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With Serious TEAEs
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
A serious TEAE is any untoward medical occurrence or effect that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, and was an important medical event.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With TEAEs Leading to Drug Discontinuation
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first.
Number of participants with TEAEs leading to study drug discontinuation were reported.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With TEAEs Leading to Infusion Interruption
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first.
Number of participants with TEAEs leading to infusion interruption were reported.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With TEAEs Leading to Dose Delayed
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first.
Number of participants with TEAEs leading to dose delayed were reported.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With TEAEs Leading to Dose Reduction
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
TEAEs were defined as AEs with an onset date on or after the first dose of study drug, and within 30 days of the last dose of study drug or prior to the start of a new anti-cancer treatment, whichever occurred first.
Number of participants with TEAEs leading to dose reduction were reported.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 1: Number of Participants With Adverse Event of Clinical Interest (AECIs)
大体时间:From start of study drug up to 30 days after last dose (up to 3.7 months)
|
AECIs (serious or nonserious) were those TEAEs which were of scientific and medical concern specific to the TAK-853.
AECIs for TAK-853 included: 1. Ocular TEAEs, 2. Pneumonitis TEAEs, 3. Peripheral neuropathy TEAEs and 4. Infusion related TEAEs.
|
From start of study drug up to 30 days after last dose (up to 3.7 months)
|
|
Phase 2: Objective Response Rate (ORR) Assessed by Investigator With Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
大体时间:Up to 7.2 months
|
ORR was defined as the percentage of participants who achieved a confirmed Partial Response (PR) or confirmed Complete Response (CR) during the study using RECIST 1.1.
Complete response (CR): Disappearance of all target lesions.
All pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 millimeters (mm).
Partial response (PR): At least a 30% decrease in the sum of diameters (SoD of target lesions, taking as reference the baseline SoD).
|
Up to 7.2 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Phase 1: Maximum Observed Plasma Concentration (Cmax) of TAK-853 and Total Antibody (TAb)
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
Pharmacokinetic (PK) parameters were calculated using standard non-compartmental methods.
Cmax of TAK-853 and TAb were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: Cmax of N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)- Maytansine (DM4) and S-methyl DM4
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
Cmax of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: Area Under the Plasma Concentration-Time Curve Until Tlast (AUClast) and Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of TAK-853 and TAb
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
AUClast and AUCinf of TAK-853 and TAb were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: AUClast and AUCinf of DM4 and S-methyl DM4
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
AUClast and AUCinf of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: Terminal Half-Life (t1/2) of TAK-853, TAb, DM4 and S-methyl DM4
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
t1/2 of TAK-853, TAb, DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: Total Clearance (CL) of TAK-853 and TAb
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
CL of TAK-853 and TAb were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: Apparent Clearance (CL/F) of DM4 and S-methyl DM4
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
CL/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Phase 1: Volume of Distribution at Steady State (Vss) of TAK-853, TAb and Apparent Volume of Distribution During the Terminal Phase (VZ/F) of DM4 and S-methyl DM4
大体时间:Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
PK parameters were calculated using standard non-compartmental methods.
Vss of TAK-853, TAb and VZ/F of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 2, 4, 6, 24, 48 hours post-infusion, and Days 4, 5, 8, and 15 post-infusion
|
|
Number of Participants With Immunogenicity of TAK-853
大体时间:From start of study drug up to 8.2 months
|
Blood samples were collected to measure the presence of TAK-853 antibodies (ADA).
Seronegative was defined as a participant with negative ADA at baseline and negative ADA at post-treatment.
Treatment-emergent ADA was defined as a participant with negative ADA at baseline and positive ADA at post-treatment.
Treatment-unaffected ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was less than or equal to 4-fold compared to baseline.
Treatment-enhanced ADA was defined as a participant with positive ADA at baseline and post-dose titer increase that was greater than 4-fold compared to baseline.
|
From start of study drug up to 8.2 months
|
|
Phase 2: Duration of Response (DOR) Assessed by Investigator With RECIST 1.1
大体时间:From first documented confirmed CR or PR until first documentation of PD (up to 7.2 months)
|
DOR was defined as the time from the first observation of CR/PR (whichever is first recorded) to the first date at which progressive disease is objectively documented per RECIST 1.1, or death due to any cause, whichever occurs first.
DOR was estimated using the Kaplan-Meier method.
|
From first documented confirmed CR or PR until first documentation of PD (up to 7.2 months)
|
|
Phase 2: Plasma Concentrations of TAK-853 and TAb
大体时间:Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
|
Plasma concentrations of TAK-853 and TAb were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
|
|
Phase 2: Plasma Concentrations of DM4 and S-methyl DM4
大体时间:Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
|
Plasma concentrations of DM4 and S-methyl DM4 were reported at cycle 1 and cycle 3.
|
Cycle 1 and 3: pre-infusion, 1-hour and Day 8 post-infusion
|
合作者和调查者
赞助
调查人员
- 研究主任:Study Director、Takeda
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TAK-853-1501
- jRCT2031240057 (注册表标识符:jRCT)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 树液
- 国际碳纤维联合会
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.